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Abstract
Purpose Multiple sclerosis (MS) has been proposed as a pos-
sible differential diagnosis for Fabry disease (FD). The aim of
this work was to evaluate the involvement of corpus callosum
(CC) onMR images and its possible role as a radiological sign
to differentiate between FD and MS.
Methods In this multicentric study, we retrospectively evalu-
ated the presence of white matter lesions (WMLs) on the
FLAIR images of 104 patients with FD and 117 patients with
MS. The incidence of CC-WML was assessed in the two
groups and also in a subgroup of 37 FD patients showing
neurological symptoms.
Results WMLs were detected in 50 of 104 FD patients
(48.1%) and in all MS patients. However, a lesion in the CC
was detected in only 3 FD patients (2.9%) and in 106 MS
patients (90.6%). In the FD subgroup with neurological symp-
toms, WMLs were present in 26 of 37 patients (70.3%), with
two subjects (5.4%) showing a definite callosal lesion.
Conclusion FD patients have a very low incidence of CC
involvement on conventional MR images compared to MS,
independently from the clinical presentation and the overall
degree of WM involvement. Evaluating the presence of CC
lesions on brain MR scans can be used as a radiological sign
for a differential diagnosis between MS and FD, rapidly ad-
dressing the physician toward a correct diagnosis and subse-
quent treatment options.
Keywords MRI . Corpus callosum . Fabry disease .Multiple
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Abbreviations
MS Multiple sclerosis
FD Fabry disease
CC Corpus callosum;
WMLs White matter lesions
eGFR Estimated glomerular filtration rate
CKD-
EPI
Chronic Kidney Disease Epidemiology
Collaboration
GLA α-Galactosidase A
ERT Enzyme replacement therapy
DD Disease duration
EDSS Expanded Disability Status Scale
ARR Annualized Relapse Rate
MSSS Multiple Sclerosis Severity Score
CSF Cerebrospinal fluid
Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage
disorder caused by mutation in the α-galactosidase A (GLA)
gene, resulting in a lack, or deficiency, of the enzyme GLA,
with consequent progressive accumulation of the undegraded
glycosphingolipids in different tissues [1]. Clinical presenta-
tion of FD includes autonomic neuropathies, along with a
systemic involvement, affecting kidney, hearth, gastrointesti-
nal system, and brain [2].
Cerebral involvement in FD is mainly caused by cerebro-
vascular complications, based on the cerebral vasculopathy
known to be present in the disease [3], mainly due to both
the progressive glycosphingolipid accumulation in vessels
and to the secondary arrhythmic cardiac involvement. These
include stroke, which is the most prevalent cerebrovascular
event in FD [4], along with the presence of white matter le-
sions (WMLs), often clinically asymptomatic in these patients
[5].
Multiple sclerosis (MS) is a chronic inflammatory neuro-
degenerative disease of the central nervous system (CNS)
characterized by demyelination and axonal loss [6]. On MR
scan, MS is characterized by the presence of demyelinating
plaques in characteristic locations, such as juxtacortical,
periventricular, infratentorial, and spinal cord [7]. In particu-
lar, corpus callosum (CC) involvement is typical in MS, since
up to the 95% of MS patients show abnormalities of this
region on conventional MRI sequences [8–10]. However,
CC involvement is not pathognomonic or exclusive of MS,
due to its presence in other demyelinating and inflammatory
diseases of the CNS [11].
Even if different patterns of systemic and neurological
manifestations are present in these two conditions, due to the
incidence of WMLs in FD, MS has been proposed as a pos-
sible differential diagnosis [12, 13].Misdiagnosis ofMS could
lead to a delayed start or even a wrong treatment option;
therefore, the search for a sign, which can allow a differential
diagnosis between these two conditions, is crucial.
To date, an evaluation of incidence of WMLs of the CC of
FD patients has never been performed. The aim of this work
was to evaluate the involvement of CC on conventional MR
images and its possible role as a radiological sign for a differ-
ential diagnosis between FD and MS. With this aim, we ret-
rospectively evaluated 104 and 117 brainMR scans of FD and
MS patients, respectively, to determine the incidence of
WMLs in the CC of these patients.
Methods
Subjects
In this multicentric retrospective study, we analyzed a cohort
of FD patients recruited through the FD specialized care
clinics of seven hospitals. The clinical and radiological data
collected in this study were obtained at different centers as part
of the clinical workup deemed necessary for each patient, and
only the authorization for transferral of data was obtained
from the Local Ethical Committee of the coordinating center.
Inclusion criteria were as follows: genetically proven FD,
availability of brain MRI scans, and signed informed consent
for participation in the study. Diagnosis of FD was confirmed
using biochemical or genetic testing, and both adult male and
female participants were approached to participate, without
age limitations. Indications for brain MRI varied between
and within centers including but not limited to routine screen-
ing scans, headache, transient neurologic symptoms, and
acute stroke evaluations.
Age was recorded at the time of the brain MR scan.
Hypertension, diabetes mellitus, cardiac arrhythmia, left ven-
tricular hypertrophy, renal failure (considered as present when
the estimated glomerular filtration rate—eGFR—of the pa-
tient was <90 ml/min), proteinuria (considered as present
when the patient scored a value >150 mg/24 h), and the pres-
ence of neurological symptoms (including stroke, cephalalgia,
acroparesthesia, etc.) were recorded based on the prior diag-
nosis at each specialized care center participating in this study.
History of FD-associated pain in hands and feet, decreased
sweating, and gastrointestinal problems characteristic for FD
were also recorded for each participant. Finally, history of
prior stroke or transient ischemic attacks, hemodialysis, renal
or cardiac transplant, current use of tobacco or alcohol, and
treatment with enzyme replacement therapy (ERT) were ab-
stracted by a clinician experienced in FD frommedical records
or obtained in direct interviews.
Renal function was expressed as eGFR, calculated with the
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation [14]. Other laboratory values were measured
using standard hospital laboratory techniques. GLA enzyme
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activity was classified as Babsent^ (<1% of normal values) or
Bresidual^ (1–5% of normal values), because of the different
measurement methods used in the recruiting centers (plasma,
leukocytes, etc.).
Data were recorded by each center in dedicated case report
forms and then entered into a central database at the coordi-
nating center, according to good clinical practice guidelines.
From the whole FD group, a subgroup of patients with
neurological symptoms was identified in order to determine
the incidence of CC lesions in a group of subjects in which a
suspect of MS could have been clinically hypothesized.
Along with FD patients, the MR brain scans of a group of
relapsing remitting-MS patients, acquired in a single center on
different scanner, were selected of comparable age and sex
with the group of FD patients, and analyzed in this study.
All MS patients fulfilled the revised McDonald criteria for
MS diagnosis [15]. Clinical variables were retrospectively
collected from clinical records within 2 weeks from the MR
scan. These included, along with disease duration (DD), mea-
sures from the first occurrence of symptoms clearly related to
the disease: Expanded Disability Status Scale (EDSS),
Annualized Relapse Rate (ARR), and Multiple Sclerosis
Severity Score (MSSS).
MRI data evaluation
For all subjects included in the analysis, MRI brain scans were
visually assessed by two neuroradiologists, blinded for the
diagnosis and in consensus (A.B. and E.T.), who rated the
presence and the load of WMLs as suggested by a recent
multicenter MR study on FD [16]. Briefly, this score identifies
the presence of WMLs, depending on the anatomical locali-
zation, in periventricular and deep hemispheric white matter.
For each locations, a score ranging from 0 to 3 (with 0 indi-
cating absence of WMLs, and 3 largest and confluent chronic
WMLs) was given, with a single subject who could therefore
in our study range from aminimum of 0 (indicating absence of
WMLs) to 6.
The evaluation of possibleWMLs was carried out on fluid-
attenuated inversion recovery (FLAIR) images acquired, de-
pending on the scanner, with different orientations on ≤5 mm-
thick slices at ≥0.5 Tesla. A complete list of all the subjects
included in this study grouped according to MR scanner field
strength is reported in Table 1.
The visual assessment of CC involvement was performed
considering all FLAIR images available per patient, evaluat-
ing the portion of CC running from the midline to a plane
passing through the external wall of the lateral ventricles on
both sides. Sagittal planes were visually investigated firstly.
Where available, axial and coronal FLAIR images were also
inspected, to confirm the data recorded on the sagittal plane.
Where 3D-FLAIR images were available, multiplanar
reconstructions were generated and all three planes were
inspected, starting from the sagittal one.
Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Science (SPSS) package (SPSS Inc., ver-
sion 17.0, Chicago, IL). An unpaired t test was used for com-
paring ages and Fazekas scores between the FD and the MS
groups, while a chi-squared test was used to determine differ-
ences in term of sex. A p = 0.05 was set to indicate a statisti-
cally significant difference. Finally, no Cohen’s coefficient
was needed to evaluate the performance of the evaluation,
since the two neuroradiologists performed the analysis in
consensus.
Results
One hundred and four FD patients (64 women, 61.5%) were
included in the study. Mean age was 43 years (with a standard
deviation of 13.4 years), ranging from 13 to 72 years. Activity
of the GLA enzyme was absent in 29 patients (27.9%), while
it showed a residual activity in 75 patients (72.1%); distinct
GLA gene mutations were represented and the clinical mani-
festations were different, with multiple organ involvement.
Finally, 72 patients were treated with ERT (69.2%, with a
mean duration of 58.9 ± 69.5 months). Demographic and clin-
ical information of all FD patients included in the analysis are
listed in Table 2, while a complete list of the different genetic
mutations is reported in Table S1 of the Supplementary
Materials.
Along with the FD patients, 117 MS patients (79 women,
67.5%) were included in the study. Mean age was 38 years
(with a standard deviation of 11.1 years), ranging from 12 to
65 years. These patients showed a mean DD of 6.3 years, and
a mean EDSS score of 3.4. Complete demographic and clin-
ical information of MS patients included in the analysis are
listed in Table 3. The FD and MS groups were not significant-
ly different for age and sex.
From the 104 FD patients, a subgroup of 37 subjects with
neurological symptoms was identified (M/F = 13/24). Mean
age of this subgroup of patients was 46 years (with a standard
deviation of 12.6 years), ranging from 17 to 72 years. Activity
Table 1 Subjects
included in this study
grouped according to
MR scanner field
strength
FD MS
0.5 Tesla 28/104 na
1.5 Tesla 41/104 32/117
3 Tesla 35/104 85/117
FD Fabry disease, MS multiple sclerosis,
na not applicable
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of the GLA enzyme was absent in 12 patients (32.4%), and
residual in the remaining 25 patients (67.6%). Similarly to the
entire group, distinct GLA gene mutations were represented
and the clinical manifestations were different, with multiple
organ involvement. Finally, a total of 30 patients (81.1%) were
under treatment with ERT (with a mean duration of
64.3 ± 59.1 months). Demographic and clinical information
of the FD patents with neurological symptoms included in the
analysis are also listed in Table 2.
Among the total of 104 FD patients, WMLs were detected
in 50 subjects (48.1%), with a mean Fazekas score of 2.3
(±1.71). In the entire FD population, a lesion in the CC was
detected in only three subjects (2.9%) (Table 4). An example
of WML load in FD patients is shown in Fig. 1.
All MS patients showed someWMLs in the periventricular
or deep WM regions, with a mean Fazekas score of 2.6
(±1.27), not significantly different from that of FD patients.
Instead, the incidence of lesions in the CC was significantly
higher in the MS group compared to FD, with at least one
definite callosal lesion present in 106 of 117 MS patients
(90.6%) (Table 4).
In the subgroup of 37 FD patients with neurological symp-
toms, WMLs were present in 26 subjects (70.3%), with a
mean Fazekas score (2.5 ± 1.94) similar to the one of the other
two groups. Even in neurologically symptomatic FD patients,
a low incidence of CC lesion was observed, with only two
subjects (5.4%) showing a definite WML at that level.
The individual Fazekas scores of the three patients with a
CC lesion were 1, 3, and 5, respectively, with a mean value of
3.0.
Measures of diagnostic performance relative to CC in-
volvement in the clinical setting of a differential diagnosis
between MS and FD are listed in Table 5.
Finally, when analyzing the MR characteristic of the
callosal lesions in FD, no WML affecting the CC resembled
the typical appearance of a demyelinating plaque, in terms
neither of anatomical location nor of morphological appear-
ance (Fig. 2).
Discussion
This is, to the best of our knowledge, the first study that in-
vestigates the incidence of WMLs in the CC in a relatively
large group of FD patients with the aim of looking for a ra-
diological sign that may help to distinguish this disease from
MS. We have shown that in FD patients, CC is very rarely
involved on conventional MR images compared to MS,
Table 4 Distribution of CC involvement in FD and MS patients
FD MS TOT
Positive CC involvement 3 106 109
Negative CC involvement 101 11 112
TOT 104 117 221
CC Corpus callosum, FD Fabry disease, MS multiple sclerosis
Table 2 Subjects demographic
and clinical variables of all FD
patients included in the study
FD (all patients) FD (with neurological symptoms)
Age (mean ± SD) 43 ± 13.4 (range 13–72) 46 ± 12.6 (range 17–72)
Sex (M/F) 40/64 13/24
Neurological symptoms 37/104 na
Hypertension 24/104 16/37
Diabetes 3/104 2/37
Arrhythmia 7/104 3/37
Left ventricular hypertrophy 51/104 21/37
Renal failure 48/104 21/37
Proteinuria 49/104 18/37
Tabagism 9/104 4/37
Age is expressed in years
FD Fabry disease, SD standard deviation, na not applicable
Table 3 Subjects demographic and clinical variables of MS patients
included in the study
MS
Age (mean ± SD) 38 ± 11.1 (range 12–65)
Sex (M/F) 38/79
DD (mean ± SD) 6.3 ± 7.3
EDSS (median) 3.25 (range 1.5–7.0)
ARR (median) 0.60 (range 0.17–4.03)
MSSS (median) 4.68 (range 1.15–8.70)
Age and DD are expressed in years
MSmultiple sclerosis, SD standard deviation, EDSS Expanded Disability
Status Scale, ARR Annualized Relapse Rate, MSSS Multiple Sclerosis
Severity Score, DD disease duration. SD standard deviation
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independently from the clinical presentation, and that this
evaluation can be used to differentiate MS from FD patients.
N e u r o p a t h o l o g y s t u d i e s h a v e s h ow n t h a t
glycosphingolipid storage in FD is not restricted to the vascu-
lar bed, but it is present in different brain regions which are
typically affected by neurodegenerative disorders [17, 18].
Despite the poorly understood physiopathological mecha-
nisms of this phenomenon, the cerebrovascular involvement
present in FD induces alterations radiologically identified as
WMLs, considered a characteristic FD neuroradiological sign
[19]. A recent study showed that age and prior history of
stroke were predictors of the WML load in FD, while cardiac
involvement and treatment with ERTwere associated, respec-
tively, with a higher and a lower WML burden [20].
In the last years, FD has been proposed as a possible dif-
ferential diagnosis for MS, due to the heterogeneity and the
overlap of the clinical presentation of both disorders [12, 13].
Brain MR is usually performed in FD, and in some patients,
WM abnormalities are present, showing a pattern somehow
similar between MS and FD. Indeed, the load of WMLs may
mimic the appearance of MS [3]; thus, a careful differential
diagnosis should be performed. However, to date, a definite
sign that could help in a radiological differential diagnosis
between these two conditions is lacking.
The involvement of CC in MS is a typical feature of the
disease [8–10]. MS lesions in CC may show some degrees of
heterogeneity, being present as narrow hyperintense band
along the undersurface (calloso-septal interface) of CC, or as
radiated T2w-hyperintensity going from the undersurface to
the deep callosal fibers, or as ovoid lesions which radiates into
the pericallosal WM, known as Dawson’s fingers [9, 21, 22].
However, it is also well known that CC involvement is not
specific of MS, being present in other neuroinflammatory or
acquired demyelinating diseases, such as neuromyelitis
optica, acute disseminated encephalomyelitis, Susac’s syn-
drome, CNS vasculitis, and systemic lupus erythematosus
[11].
To date, no studies have been performed on large number
of FD patients to evaluate the incidence of CC involvement in
this disease, and its possible role in the differential diagnosis
with MS. Indeed, this possibility has been only suggested in a
previous work [12], but never formally tested in two groups of
FD and MS patients.
Different case reports in the last years reported the initial
misdiagnosis of MS in subjects who, later, turned out to be FD
patients [23–26]. In these cases, patients did not show CC
involvement, with WMLs being variably present in
juxtacortical areas, periventricular WM, basal ganglia, pons,
and cerebellar WM. Interestingly, in another case report [27],
few T2-hyperintense lesions involving the CC were reported
in a patient later diagnosed with a coexistence of bothMS and
FD, allowing us to speculate that the involvement of CC was
indeed linked to MS, rather than FD.
On reflection, in a recent case report [28], a patient with FD
showed CC involvement on FLAIR images. This finding is
only apparently in conflict with ours. In fact, as the involve-
ment of CC in FD is very infrequent (2.9%), but not totally
absent, this result may fall in the low rate of false positive
cases, in which a complementary examination, such as a spine
MRI (which has already been suggested to help in
Fig. 1 Axial FLAIR images of
two FD patients (a-b) with a
Fazekas score of 6, showing
confluent areas of white matter
hyperintensity. In both cases, the
corpus callosum is spared from
white matter lesions (not shown)
Table 5 Measures of diagnostic performance for CC involvement in
the clinical setting of differential diagnosis between MS and FD
Sensitivity 91%
Specificity 97%
Positive predictive value (PPV) 97%
Negative predictive value (NPV) 90%
Accuracy 94%
Positive likelihood ratio 30.33
Negative likelihood ratio 0.09
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distinguishing between MS and FD [12]), could help to raise
the accuracy of MRI in this differential diagnosis.
Furthermore, it should be noted that in the three cases of
positive CC involvement in FD patients, these lesions did
exhibit neither anatomical localization nor morphological fea-
tures of a classic MS plaque (e.g., perivenular location,
Dawson’s fingers). This finding, together with the low
WML load of these patients, allows for an even stronger spec-
ulation about the high positive predictive value of this sign in
excluding MS from the possible differential diagnosis of FD.
Along with the evaluation of WMLs by means of conven-
tional MRI, microstructural WM changes have been detected
in FD independent of the presence of WMLs in most, but not
all, studies [29–32]. In particular, both a reduction of the frac-
tional anisotropy and an increase in the mean diffusivity in the
CC were found in FD patients suggesting that even if clear
lesions are not visible on conventional MRI, CC is not
completely spared by the disease. Due to the retrospective
nature of the present work, however, we were not able to
explore the degree of microstructural changes in those patients
who showed an involvement on conventional MRI. For this
reason, further studies should be performed to investigate a
possible relationship between the involvement of CC on con-
ventional MRI and the microstructural changes by means of a
diffusion tensor imaging analysis.
In addition, other biochemical and neuroradiological find-
ings have been suggested as useful when considering a possi-
ble differential diagnosis between these two conditions. In
particular, the presence of oligoclonal bands in the cerebrospi-
nal fluid (CSF) and the evidence of hyperintense spinal lesions
on MRI scan have both been reported as uncommon findings
in FD [12]. However, both these procedures are not routinely
performed in the diagnostic workup of FD patients, and there-
fore, their utility is relatively limited in daily clinical practice.
Our results fill this gap, providing an easy to identify finding
that can be used as a radiological sign for differential diagnosis
between MS and FD on the routinely performed brain MR
scans. Nonetheless, to further elucidate the possible relations
between CSF data abnormalities, spinal cord lesions, and CC
involvement in these two populations and their combined
diagnostic accuracy, future multimodal longitudinal studies
are warranted.
Some further limitations should be considered in the pres-
ent study. In particular, due to the multicentric nature of our
retrospective report, the FLAIR images used for the evaluation
were not acquired on the same scanner or with the same ge-
ometry, in terms of both spatial resolution and orientation
planes. Indeed, not all MR scans included a sagittal FLAIR
(or a 3D-FLAIR, which could allow for a multiplanar recon-
struction), which is known to reliably detect CC lesions [33,
34]. However, this occurred in only 21 of our 104 subjects
(20.2%), while in the majority of the cases, a sagittal FLAIR
sequence was available, or a 3D geometry was used, with a
voxel size of 1 × 1 × 1 mm3. To test if the use of 3D-FLAIR
could help the neuroradiologists in detecting smaller WMLs
in FD, thus increasing the rate of lesion detection in the CC,
further prospective studies should be performed.
Another limitation, always referable to the retrospective
nature of the study, has to be researched in the different pro-
portion of MR scans performed at various field strengths be-
tween the two groups, which could lead to a possible bias
given the inferior sensitivity of 0.5 TMRI for WML detection
compared to high field scanners. Indeed, an ancillary analysis
performed to compare the incidence of CC lesions in the sub-
group of patients studied on the same 3Tscanner (35 FD vs 85
MS patients) showed a similar results in the detection of
callosal lesions in the two groups (data not shown).
However, prospective studies with the inclusion of MS ac-
quired on low field scanner are warranted to confirm our
results.
Furthermore, the inclusion of MS patients with definite
diagnosis, according to the McDonald criteria [35], may have
led to a higher incidence of callosal lesion in our control
group. However, our sample of MS patients had a similar
WML load in both periventricular and deep white matter re-
gions. Although the Fazekas score was not created to quantify
theWML load inMS, we used it to compare these two groups,
and only 5 out of 117 MS subjects (4.3%) scored a Fazekas of
6, therefore suggesting a heavy WML burden. However, to
further clarify the role of the evaluation of CC as a radiological
Fig. 2 Sagittal (a) 3D-FLAIR
and the corresponding coronal
MPR (b) of an FD patient, with a
Fazekas score of 3, showing a
white matter lesion in the right
aspect of the body of the corpus
callosum (arrows)
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sign for the differential diagnosis between MS and FD, a pro-
spective study with the inclusion of probable MS patients
should be performed. Moreover, even if the Fazekas score
has proved to be close correlated to quantitativemeasurements
[36], it only allows for a visual assessment of the lesion load
and that more objective and quantifiable methods are available
to quantify the WML burden.
However, again due to the retrospective nature of our study,
3D-FLAIR imaging, which is very suitable for this analysis,
was available only in 34 of our 104 FD patients (32.7%). For
these reasons, future prospective studies with objective and
quantifiable assessment of the lesion load may be performed
to confirm our results.
Conclusions
In conclusion, we showed that FD patients show a very low
incidence of CC involvement on conventional MRI images
compared to MS and that the presence of callosal lesions is
somehow independent by the clinical presentation. Our result
proves that the evaluation of CC can be used as a radiological
sign for differential diagnosis between MS and FD, rapidly
addressing the physician toward a correct diagnosis and sub-
sequent treatment options.
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